Intellia Competitors

Stocks . USA . 
Stock . Intellia Therapeutics
NTLA Stock  USD 11.64  0.69  5.60%   
Intellia Therapeutics competes with Editas Medicine, Caribou Biosciences, Crispr Therapeutics, Verve Therapeutics, and Beam Therapeutics; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Intellia Therapeutics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Intellia Therapeutics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Intellia Therapeutics Correlation with its peers.
For information on how to trade Intellia Stock refer to our How to Trade Intellia Stock guide.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Intellia Therapeutics competition on your existing holdings.
  
Build AI portfolio with Intellia Stock
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
5.4011.3617.32
Details
Intrinsic
Valuation
LowRealHigh
11.5017.4623.42
Details
Naive
Forecast
LowNextHigh
5.3111.2617.22
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
10.2912.1814.07
Details

Intellia Therapeutics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Intellia Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Intellia and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Intellia Therapeutics does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
SANA
+ 0.97
CRBU
PRME
+ 0.96
CRSP
SANA
+ 0.92
CRSP
SANA
+ 0.9
PRME
CRSP
+ 0.89
CRBU
PRME
+ 0.89
BEAM
  
High negative correlations   
FATE
- 0.2
VERV
PRME
- 0.17
FATE
DNA
- 0.08
FATE
FATE
- 0.08
BEAM
FATE
- 0.06
CRSP

Risk-Adjusted Indicators

There is a big difference between Intellia Stock performing well and Intellia Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Intellia Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
EDIT  5.17  0.47  0.14  0.28  5.09 
(6.39)
 12.60 
(8.54)
 26.63 
CRBU  5.53  1.26  0.23  0.58  5.09 
(6.46)
 13.66 
(8.49)
 30.01 
CRSP  3.04  0.70  0.15 (58.01) 3.23 
(3.51)
 7.09 
(5.76)
 25.64 
VERV  4.56  1.64  0.38  2.08  2.86 
(6.12)
 8.49 
(5.62)
 83.78 
BEAM  3.00  0.02 (0.03)(0.15) 4.79 
(2.83)
 5.84 
(4.49)
 20.92 
FATE  4.76 (0.49) 0.00  0.00  0.00 
 0.00 
 9.40 
(9.68)
 29.40 
VRTX  1.35 (0.29) 0.00 (0.09) 0.00 
 0.00 
 2.54 
(2.62)
 11.44 
DNA  4.69  0.56  0.16  0.34  4.43 
(5.74)
 14.73 
(7.45)
 29.69 
PRME  6.63  1.93  0.24 (1.35) 6.03 
(8.57)
 15.00 
(10.81)
 41.91 
SANA  5.05  1.31  0.30  1.10  3.84 
(6.49)
 12.50 
(7.22)
 34.30 
All Fundamental Data

Intellia Therapeutics Competitive Analysis

The better you understand Intellia Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Intellia Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Intellia Therapeutics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
NTLA EDIT CRBU CRSP VERV BEAM FATE VRTX DNA PRME
 5.60 
 11.64 
Intellia
 0.40 
 2.51 
Editas
 0.98 
 2.03 
Caribou
 2.46 
 56.26 
Crispr
 0.00 
 11.13 
Verve
 2.18 
 19.71 
Beam
 3.51 
 1.10 
Fate
 2.62 
 456.87 
Vertex
 2.02 
 13.14 
Ginkgo
 4.59 
 3.74 
Prime
Market Volatility
(90 Days Market Risk)
Somewhat reliable
Dangerous
Dangerous
Very steady
Relatively risky
Not too volatile
Dangerous
Very steady
Moderately volatile
Very risky
Market Performance
(90 Days Performance)
OK
OK
Solid
Good
Good
Very Weak
Weak
Very Weak
Good
Solid
Odds of Financial Distress
(Probability Of Bankruptcy)
Below Average
Quite High
Below Average
Low
Below Average
Low
High
Low
Quite High
Below Average
Current Valuation
(Equity Enterprise Value)
Under Valued
Under Valued
Over Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Over Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Buy
Not Available
Not Available
Not Available
Not Available
Buy
Buy
Hold
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Cautious Hold
Cautious Hold
Strong Sell
Hold
Strong Sell
Strong Sell
Strong Hold
Hold
Strong Sell
Current Ratio
7.24
12.67
12.23
17.57
11.55
4.64
6.55
4.7
11.84
6.7
Net Asset
1.19 B
341.59 M
313.31 M
2.24 B
647.39 M
1.1 B
440.69 M
22.53 B
1.38 B
297.51 M
Profit Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
-0.0891
-1.99
N/A
EBITDA
(523.98 M)
(231.28 M)
(166.62 M)
(447.31 M)
(221.91 M)
(383.98 M)
(176.58 M)
486.3 M
(484.39 M)
(196.34 M)
Operating Margin
-7.27
-7.58
-18.24
-171.59
-1.11
-15.97
-25.34
0.37
-1.82
-36.03
Current Valuation
892.69 M
19.87 M
8.42 M
3.35 B
565.6 M
964.4 M
(26.41 M)
112.77 B
686.75 M
504.12 M
Price To Book
1.64
3.36
0.88
2.72
2.1
1.8
0.45
7.3
1.19
4.93
Retained Earnings
(2.18 B)
(1.47 B)
(448.39 M)
(1.37 B)
(743.01 M)
(1.57 B)
(1.4 B)
9.61 B
(5.84 B)
(687.21 M)
Current Asset
77.63 M
144.99 M
N/A
232 M
N/A
2.89 B
47.4 M
1.41 B
10.07 B
N/A
One Year Return
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
-0.31
Beta
2.21
2.16
2.48
1.82
2.24
2.08
2.19
0.41
1.49
2.34
Number Of Employees
403
246
147
393
274
393
181
6.1 K
834
214
Equity Positions Weight
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
99.55
Shares Outstanding
103.58 M
83.71 M
93 M
86.36 M
89.31 M
100.56 M
114.63 M
256.8 M
46.34 M
134.5 M
Three Year Return
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
3.82
Cash Flow From Operations
(348.88 M)
(210.28 M)
(138.2 M)
(142.77 M)
(157.69 M)
(347.25 M)
(122.87 M)
(492.6 M)
(319.58 M)
(122.86 M)
Total Debt
210.2 M
35.03 M
26.49 M
223.69 M
69.98 M
161.43 M
85.27 M
1.75 B
467.73 M
40.79 M
Return On Equity
-0.58
-1.41
-0.53
-0.2
-0.34
-0.38
-0.49
-0.0564
-0.58
-1.15
Return On Asset
-0.3
-0.37
-0.29
-0.13
-0.19
-0.19
-0.24
0.12
-0.17
-0.4
Number Of Shares Shorted
28.87 M
8.52 M
4.62 M
25.3 M
3.63 M
23.66 M
9.46 M
4.19 M
10.34 M
21.66 M
Book Value Per Share
7.53
0.75
2.34
21.18
5.33
11.52
2.52
64.2
11.84
0.84
Current Liabilities
10.7 M
6.92 M
N/A
78 M
N/A
706.6 M
14.68 M
506.35 M
3.1 B
N/A
Total Asset
1.19 B
341.59 M
313.31 M
2.24 B
647.39 M
1.1 B
440.69 M
22.53 B
1.38 B
297.51 M
Debt To Equity
0.079
0.043
0.08
0.12
0.003
0.25
0.19
0.063
0.032
0.18
Short Ratio
5.98
2.57
2.4
6.55
0.46
9.87
5.93
3.34
6.47
3.98
Target Price
37.11
3.38
9.14
80.91
13.13
44.07
5.62
505.19
8.67
7.36
Shares Owned By Institutions
93.39
57.56
53.16
76.06
94.68
98.03
93.94
97.7
78.01
55.45
Market Capitalization
1.28 B
210.12 M
190.66 M
4.98 B
994.04 M
2.03 B
126.1 M
117.32 B
769.11 M
527.22 M
Price To Earning
-19.91
-7.02
N/A
17.33
5.45
37.48
-4.35
24.57
25.51
14.4
Price To Earnings To Growth
-0.0969
N/A
0.5
-0.21
N/A
-2.3
N/A
0.58
N/A
N/A
Price To Sales
28.03
5.86
19.22
132.22
16.68
31.87
9.46
10.57
3.24
137.08
Net Income
(519.02 M)
(237.09 M)
(149.1 M)
(366.25 M)
(198.71 M)
(376.74 M)
(186.26 M)
(535.6 M)
(547.03 M)
(195.88 M)
Earnings Per Share
-5.23
-3.04
-1.62
-4.49
-2.11
-4.61
-1.49
-3.84
-8.91
-1.61
Shares Owned By Insiders
4.9
0.33
9.82
1.68
5.1
1.0
1.73
0.14
6.87
23.65
Revenue
57.88 M
32.31 M
9.99 M
35 M
32.33 M
63.52 M
13.63 M
11.02 B
227.04 M
2.98 M
Working Capital
529.01 M
212.09 M
188.73 M
1.85 B
499.84 M
696.08 M
253.39 M
6.03 B
495.48 M
173.93 M
Cash And Equivalents
874.28 M
452.56 M
339.92 M
2.07 B
293.56 M
1.09 B
568.85 M
9.77 B
561.57 M
146.66 M
Cash Per Share
11.5
6.59
5.59
26.48
4.9
15.9
5.86
38.06
0.84
6.39
Gross Profit
(417.32 M)
(161.41 M)
(119.76 M)
(400.08 M)
(150.82 M)
(302.07 M)
(102.19 M)
5.89 B
190.02 M
(151.57 M)
Day Typical Price
11.79
2.5
2.06
56.92
11.13
19.78
1.12
460.97
13.2
3.72
Accumulation Distribution
0.0668
0.0698
0.0829
0.0427
N/A
0.0328
0.0684
0.0322
0.0594
0.0997
Market Facilitation Index
0.82
0.18
0.18
2.5
N/A
0.66
0.08
15.14
0.81
0.39
Daily Balance Of Power
(0.84)
(0.06)
(0.11)
(0.57)
0.0
(0.67)
(0.50)
(0.81)
0.321
(0.46)
Period Momentum Indicator
(0.69)
(0.01)
(0.02)
(1.42)
N/A
(0.44)
(0.04)
(12.29)
0.26
(0.18)
Rate Of Daily Change
0.94
1.0
0.99
0.98
1.0
0.98
0.96
0.97
1.02
0.95
Day Median Price
11.87
2.49
2.08
57.25
11.13
19.81
1.13
463.02
13.23
3.72
Price Action Indicator
(0.57)
0.015
(0.06)
(1.70)
N/A
(0.32)
(0.05)
(12.29)
0.045
(0.07)
Relative Strength Index
62.44
58.89
71.39
67.77
72.99
56.97
58.37
50.48
67.32
60.81
Coefficient Of Variation
908.37
705.12
418.18
612.46
644.22
20971.25
(109,975)
(1,805)
669.36
490.47
Mean Deviation
4.39
5.17
5.53
3.04
4.56
3.0
4.76
1.35
4.69
6.63
Jensen Alpha
0.6781
0.4697
1.26
0.7036
1.64
0.0203
(0.49)
(0.29)
0.5599
1.93
Total Risk Alpha
(0.38)
(0.20)
0.4493
(0.05)
(0.21)
(0.74)
(1.08)
(0.45)
(0.15)
0.2613
Sortino Ratio
0.0774
0.1374
0.2349
0.1541
0.3797
(0.03)
N/A
N/A
0.1647
0.2371
Downside Variance
43.26
30.32
41.04
13.62
18.07
23.82
N/A
N/A
23.26
46.61
Standard Deviation
5.93
6.35
6.89
4.36
11.32
4.36
6.17
1.93
6.27
8.64
Kurtosis
3.27
(0.41)
(0.36)
4.14
44.04
6.43
1.22
9.56
0.842
0.726
Potential Upside
8.49
12.6
13.66
7.09
8.49
5.84
9.4
2.54
14.73
15.0
Treynor Ratio
(2.39)
0.2824
0.5783
(58.01)
2.08
(0.15)
(0)
(0.09)
0.3365
(1.35)
Maximum Drawdown
36.46
26.63
30.01
25.64
83.78
20.92
29.4
11.44
29.69
41.91
Variance
35.11
40.28
47.51
19.01
128.17
19.01
38.13
3.73
39.38
74.71
Market Risk Adjusted Performance
(2.38)
0.2924
0.5883
(58.00)
2.09
(0.14)
0.0056
(0.08)
0.3465
(1.34)
Risk Adjusted Performance
0.0938
0.1184
0.1937
0.1344
0.1293
0.0119
0.008
(0.04)
0.1243
0.1667
Skewness
(1.08)
0.1342
0.0612
0.7971
6.16
(0.86)
0.1473
(2.02)
0.8521
0.6233
Semi Deviation
5.78
5.09
5.09
3.23
2.86
4.79
N/A
N/A
4.43
6.03
Information Ratio
0.0859
0.1192
0.2183
0.1304
0.1426
(0.03)
(0.02)
(0.13)
0.1266
0.1873
Value At Risk
(7.79)
(8.54)
(8.49)
(5.76)
(5.62)
(4.49)
(9.68)
(2.62)
(7.45)
(10.81)
Expected Short fall
(4.59)
(6.39)
(6.46)
(3.51)
(6.12)
(2.83)
N/A
N/A
(5.74)
(8.57)
Downside Deviation
6.58
5.51
6.41
3.69
4.25
4.88
N/A
N/A
4.82
6.83
Semi Variance
33.43
25.93
25.87
10.43
8.16
22.95
N/A
N/A
19.65
36.39

Intellia Therapeutics Competition Performance Charts

Five steps to successful analysis of Intellia Therapeutics Competition

Intellia Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Intellia Therapeutics in relation to its competition. Intellia Therapeutics' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Intellia Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Intellia Therapeutics' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Intellia Therapeutics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Intellia Therapeutics position

In addition to having Intellia Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Warren Buffett Holdings Thematic Idea Now

Warren Buffett Holdings
Warren Buffett Holdings Theme
A long-term portfolio of publicly-traded stocks on US exchanges that are owned by Warren Buffett's holding company Berkshire Hathaway. The Warren Buffett Holdings theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Warren Buffett Holdings Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Intellia Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Intellia Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Intellia Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Intellia Therapeutics Stock:
How To Invest In Intellia
Details
Is Intellia Stock a good investment?
Details
What is Intellia Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out Intellia Therapeutics Correlation with its peers.
For information on how to trade Intellia Stock refer to our How to Trade Intellia Stock guide.
You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intellia Therapeutics. If investors know Intellia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intellia Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Intellia Therapeutics is measured differently than its book value, which is the value of Intellia that is recorded on the company's balance sheet. Investors also form their own opinion of Intellia Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Intellia Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intellia Therapeutics' market value can be influenced by many factors that don't directly affect Intellia Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between Intellia Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Intellia Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intellia Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY